Antibody-drug conjugates [ADC] Market size exceeds US dollars

Pune, August 20, 2024 (GLOBE NEWSWIRE) — Antibody-drug conjugates [ADC] Market Size and Growth Analysis:

“According to SNS Insider Research, The Antibody Drug Conjugates (ADC) Market The size was estimated at USD 8.71 billion in 2023 and is expected to reach USD 24.70 billion by 2032, growing at a CAGR of 12.30% during the forecast period 2024-2032.”

Antibody-drug conjugates represent a significant advance in targeted chemotherapy, combining the specificity of antibodies with the potency of cytotoxic drugs to specifically target and destroy cancer cells. Since the approval of the first ADC in 2000, the field has experienced significant growth, with technological innovations driving new developments. ADCs are now an essential part of the treatment of various cancer subtypes, such as HER2-positive, hormone receptor-positive, triple-negative breast cancer and urothelial carcinoma.

The recent FDA approval of datopotamab deruxtecan for the treatment of metastatic HR-positive and HER2-negative breast cancer underscores the continued momentum in this field. The increasing number of cancer cases and the increasing number of survivors underscore the urgent need for advances in cancer therapy. With over 160 ADCs in development (as of April 2024) and significant investment from pharmaceutical companies, the ADC market is poised for significant expansion.

Get a sample report on antibody-drug conjugates [ADC] Market@

This report lists the key players:

• Zydus Group
• F. Hoffmann-La Roche Ltd
• Astellas Pharma Inc
• ImmunoGen, Inc.
• Daiichi Sankyo Company, Limited
• Gilead Sciences, Inc.
• ADC Therapeutics SA
• Takeda Pharmaceutical Company Limited
• AstraZeneca
• Seagen Inc.
• Pfizer Inc.
• Other players

Antibody-drug conjugates [ADC] Scope of the market report:

“Groundbreaking next-generation cancer therapies with improved efficacy and precision”

Antibody-drug conjugates (ADCs) are at the forefront of the next generation of cancer therapies, offering improved efficacy and expanding treatment options for patients. Advances in antibody engineering and linker technology have led to the development of highly potent ADCs that overcome previous challenges such as weak linkers and imprecise targeting. These innovations have resulted in ADCs that are more effective and specific, reducing collateral damage to healthy tissue.

Do you have specific questions or do you need individual research on antibody-drug conjugates? [ADC] Market, make an inquiry now@

Recent clinical trials have shown that ADCs are more effective than conventional chemotherapy in several types of cancer, including bladder cancer, breast cancer and lung cancer. For example, the combination of enfortumab vedotin and pembrolizumab has shown an overall survival rate that is almost twice as high in patients with bladder cancer compared to standard treatments. This success underscores the growing potential of ADCs to become a primary treatment for cancers that have previously been difficult to treat.

Segment analysis:

By ProductKadcyla dominated the ADC market with a 28% market share in 2023, driven by its proven efficacy in treating HER2-positive breast cancer. Its dominance is further supported by the increasing number of regulatory approvals for ADCs specifically targeted at Breast cancer.

By disease typeBreast cancer was the leading segment, accounting for 44% of the market share in 2023. The dominance of this segment is due to the high acceptance of ADCs among breast cancer patients and the large number of clinical trials focused on breast cancer ADCs. In addition, the increasing approval of ADCs for other cancers such as blood, lung, cervical and ovarian cancer indicates a promising trend towards diversification of ADC applications.

Antibody-drug conjugates [ADC] Market Key Segmentation:

By Product

• Kadyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• policy
• Other

By disease type

• Breast cancer
• Blood cancer
• Miscellaneous

By linker type

By destination

By payload type

• MMAE/ Auristatin
• Calicheamicin
• Maytansinoids
• Miscellaneous

Important regional developments:

North America held the largest market share of 48.33% in 2023, a trend that is expected to continue throughout the forecast period. The dominance is driven by a strong pipeline of new ADCs and a rapid pace of regulatory support in the region. The US, in particular, has seen significant investment in ADC R&D, with major pharma companies leading the way. Meanwhile, the Asia Pacific region is poised to witness the fastest growth, driven by rising cancer incidence and increasing adoption of ADCs as a viable treatment option. The recent launch of Zydus' biosimilar Ujivra in the region is expected to further accelerate the market growth. As more patients and healthcare providers in the Asia Pacific region adopt ADCs, the region is likely to become a major player in the global ADC market.

Current developments:

• In July 2024 Ipsen and Foreseen Biotechnology announced an exclusive global license agreement for FS001, a next-generation antibody drug conjugate (ADC) that represents an important milestone in the advancement of cancer treatment.
• AstraZeneca continues to lead the ADC market with its established ADC trastuzumab deruxtecan, which is approved for multiple indications. The company is also actively developing a new ADC, datopotamab deruxtecan. In May 2024, AstraZeneca announced a significant investment of USD 1.5 billion to establish a dedicated ADC manufacturing facility in Singapore, underscoring its commitment to this space.

Buy an Enterprise User PDF of Antibody-Drug Conjugates [ADC] Market Analysis and Outlook Report 2024-2032@

Key findings:

• Comprehensive analysis of the ADC market including key drivers, restraints, and opportunities.
• Insights into the most dominant product and disease segments with a focus on market dynamics.
• Regional analysis highlighting the leading markets and regions with the highest growth potential.
• Evaluating the recent developments and strategic moves made by key players in the ADC market.
• Detailed understanding of the competitive landscape and emerging trends in the ADC sector.

Table of Contents – Key Points

1. Introduction

2. Summary

3. Research methodology

4. Analysis of the impact of market dynamics

5. Statistical insights and trend reports

6. Competitive landscape

7. Antibody Drug Conjugates (ADC) Market Segmentation by Product

8. Antibody Drug Conjugates (ADC) Market Segmentation by Disease Type

9. Antibody Drug Conjugates (ADC) Market Segmentation by Linker Type

10. Antibody Drug Conjugates (ADC) Market Segmentation by Target

11. Antibody Drug Conjugates (ADC) Market Segmentation by Payload Type

12. Regional analysis

13. Company profiles

14. Use cases and best practices

15. Conclusion

Access full report details of Antibody Drug Conjugates (ADC) Market Analysis and Outlook Report 2024-2032@

[For more information or need any customization research mail us at [email protected]]

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry worldwide. Our company's goal is to provide our clients with the knowledge they need to navigate changing circumstances. To provide you with up-to-date, accurate market data, consumer insights and opinions so you can make decisions with confidence, we use a variety of techniques including surveys, video calls and focus groups around the world.